Filing Flows › Companies › Ionis Pharmaceuticals › Earnings quality
Ionis Pharmaceuticals earnings quality score
How much of the reported profit is backed by cash, and how many markers of managed earnings the filings show
Score51 / 100 · grade C · rank 865 of 1027
Ionis Pharmaceuticals (IONS) scores 51 of 100 for earnings quality, grade C: rank 865 of 1027 companies and 105 of 126 in health. It loses the most points on accruals of -3.5% of assets, higher than 58% of companies (profit backed by cash), adjusted earnings 42% below GAAP, Piotroski F-score 3 of 9. It earns full or near-full marks for profit about as variable as cash flow (smoothness 0.73).
What earned and lost points
| Component | What the filings show | Points | Of |
|---|---|---|---|
| Accruals | accruals of -3.5% of assets, higher than 58% of companies (profit backed by cash) | 12 | 29 |
| Montier C-score | Montier C-score 1 of 4 checks failed | 16 | 21 |
| Discretionary accruals | discretionary accruals of -1.5% of assets (modified Jones), smaller than most | 11 | 14 |
| Piotroski F-score | Piotroski F-score 3 of 9 | 5 | 14 |
| Non-GAAP gap | adjusted earnings 42% below GAAP | 0 | 14 |
| Earnings smoothness | profit about as variable as cash flow (smoothness 0.73) | 7 | 7 |
How the score is built
Eight published measures, each scored against the whole universe or on its own scale and weighted: accruals 20, discretionary accruals 10, Beneish M 15, Dechow F 15, Montier C 15, Piotroski F 10, the non-GAAP gap 10, smoothness 5. A measure that cannot be computed (Beneish for a bank, say) drops out and the rest is rescaled, so every company is scored on what applies to it.
Every company ranked → The full quality workbench, live → Ionis Pharmaceuticals: cash flow →
Computed from the companies’ own XBRL filings (latest fiscal year) by published formulas; a statistical screen, not an audit or an accusation. A low score means the reported profit shows more of the markers of managed or low-quality earnings than its peers. Not investment advice.